新英格兰医学期刊:ALEX 实验确认罗氏药物艾乐替尼医治肺癌好于克唑替尼

  • A+
所属分类:医疗资讯

新英格兰医学期刊:ALEX 实验确认罗氏药物艾乐替尼医治肺癌好于克唑替尼 。
摘 要:克唑替尼肺癌脑转移。新英格兰医学期刊:ALEX 实验确认罗氏药物艾乐替尼医治肺癌好于克唑替尼《新英格兰医科学杂志》2022年6月6日线上先给http://www.nejm.org/doi/full/10.1056/NEJMoa1704795

在未医治过的ALK呈阳性非小细胞肺癌中艾乐替尼较为克唑替尼

环境艾乐替尼(alectinib)是一种相对高度目的性的间转性淋巴肿瘤蛋白激酶(ALK)缓聚剂,在ALK呈阳性非小细胞肺癌的诊治中已展现出全身及神经中枢系统软件(CNS)的治疗效果。在以往未医治过的晚中后期ALK呈阳性非小细胞肺癌病患者中,这种病患者包含无症状的神经中枢体系迁移蔓延病患者,大家对艾乐替尼与克唑替尼相较为,开展了科学研究。方式 在一项随机化、对外开放标识的3期临床试验中,大家任意入组了303例以往没经医治的晚中后期ALK呈阳性非小细胞肺癌病患者,接纳艾乐替尼(600mg,每日2次)或克唑替尼(250mg,每日2次)。关键终点站是学者评定的无进度存活時间。主次终点站是单独审批联合会评定的无进度存活時间、发生神经中枢系统软件发展的時间、客观性反映率及总存活時间。結果克唑替尼组负相关随诊期17.6月、艾乐替尼组18.6月,随诊时间范围,艾乐替尼组152名病患者中有62例(41%)产生恶性肿瘤进度或是过世(过虑词),克唑替尼组151名病患者中有102例(68%)。学者评定的无进度存活時间艾乐替尼组显然超过克唑替尼组(艾乐替尼组12个月无进度(过虑词)存活概率68.4%[95%可信区间CI,61.0-75.9],较为克唑替尼组48.7%[95%CI,40.4-56.9],病症进度或过世的危险性比0.47[95%CI,0.34-0.65],P<0.001);艾乐替尼组负相关无进度存活時间并未做到。单独审查联合会评定的无进度存活時间結果与关键终点站結果一致。艾乐替尼组总共18名病患者(12%)发生了神经中枢系统软件进度(过虑词),与之对比,克唑替尼组是68名(45%)(得病缘故非特异风险比,0.16;95%CI,0.10-0.28;P<0.001)。艾乐替尼组126名病患者医治合理(反映率,82.9%;95%CI,76.0-88.5),克唑替尼组是114名(反映率,75.5%;95%CI,67.8-82.1)(P=0.09)。艾乐替尼组3至5级副作用较少(41%较为克唑替尼组50%)。结果在ALK新英格兰医学期刊:ALEX 实验确认罗氏药物艾乐替尼医治肺癌好于克唑替尼呈阳性非小细胞肺癌的起始医治中,与克唑替尼对比,艾乐替尼主要表现出更快的治疗效果、更低的毒副作用。《壹篇》李振爽

Alectinib versus Crizotinib in UntreatedALK-Positive Non–Small-Cell Lung Cancer

June 6, 2017DOI: 10.1056/NEJMoa1704795BackgroundAlectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non–small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease.MethodsIn a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee–assessed progression-free survival, time to CNS progression, objective response rate, and overall survival.ResultsDuring a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached. The results for independent review committee–assessed progression-free survival were consistent with those for the primary end point. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the cr新英格兰医学期刊:ALEX 实验确认罗氏药物艾乐替尼医治肺癌好于克唑替尼izotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001). A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P=0.09). Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib).ConclusionsAs compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann–La Roche; ALEX ClinicalTrials.gov number, NCT02075840.)《壹篇》系关键朝向医护人员的服务性【微信号码:yaodaoyaofang】,不因盈利为目地,不开展一切有偿服务资询和服务项目,不销售一切商品,与ASCO、CSCO等全部技术专业学好和组织并没有任何的关联和联络,都不意味着一切官方网学好发音。文章照片均来源于互联网,不做商业行为,若有著作权异议请与《壹篇》联络。不断关注点赞——【手机微信:india2080】、称赞和分享——【手机微信:india2080】是一种心态和适用。
药道网给予近期的药物新闻资讯,聚集 印度的全世界海淘药店:克唑替尼使用方法使用量。

  • 微信咨询
  • 这是我的微信扫一扫
  • weinxin
  • WhatsApp 沟通
  • 手机扫一扫二维码
  • weinxin

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: